Eli Lilly Says FDA Approved Jaypirca for Adult Patients With Previously Untreated CLL/SLL

03:43 PM EDT, 10/02/2026 (MT Newswires) -- Eli Lilly (LLY) said Friday the US Food and Drug Administration has approved an additional indication for Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, for the treatment of adult patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. Jaypirca can now be used as a first-line treatment for appropriate patients, the company said. Lilly said it is studying Jaypirca in chronic lymphocytic leukemia or small lymphocytic lymphoma in multiple phase 3 studies. Price: 1146.33, Change: -3.52, Percent Change: -0.31